Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer

BACKGROUND: The expression of programmed cell death ligand 1(PD-L1) is related to the efficacy of immune checkpoint inhibitors on patients with non-small cell lung cancer (NSCLC), but tumor tissue (TT) samples are difficult to obtain, and initial TT samples are difficult to reflect the spatial-tempo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuxin, Wang, Ting, Lv, Xin, Li, Rutian, Yuan, Ling, Shen, Jie, Li, Yan, Yan, Tingting, Liu, Baorui, Wang, Lifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093656/
https://www.ncbi.nlm.nih.gov/pubmed/32256114
http://dx.doi.org/10.2147/CMAR.S245425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093656/
https://www.ncbi.nlm.nih.gov/pubmed/32256114
http://dx.doi.org/10.2147/CMAR.S245425

Ejemplares similares